A decade of clinical development of PARP inhibitors in perspective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A decade of clinical development of PARP inhibitors in perspective

Published:2019-09 Issue:9 Volume:30 Page:1437-1447
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mateo J.^ORCID,Lord C.J.,Serra V.,Tutt A.,Balmaña J.,Castroviejo-Bermejo M.,Cruz C.,Oaknin A.,Kaye S.B.,de Bono J.S.

Funder

Prostate Cancer Foundation

Instituto de Salud Carlos III

FERO Foundation

Asociación Española Contra el Cáncer

FERO foundation

AECC-JP Barcelona

Cancer Research UK

Department of Health

NHS funding

NIHR Biomedical Research Centre

Institute of Cancer Research

National Institute for Health Research

NIHR

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz192/28846641/mdz192.pdf

Reference95 articles.

1. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005

2. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase;Bryant;Nature,2005

3. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors;Murai;Cancer Res,2012

4. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition;McCabe;Cancer Res,2006

5. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity;Bajrami;Cancer Res,2014

Cited by 474 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors;Bioorganic Chemistry;2024-10

2. Identification of mutation-independent BRCA2 protein deficiency expands diagnostics and selection of pancreatic cancer patients for personalized therapy with PARP1 inhibitors;2024-09-08

3. Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer;Cell Reports;2024-09

4. GUIDANCE: eine prospektive, biomarkerstratifizierte Phase-II-Studie zur PARP-Inhibition im kleinzelligen Lungenkarzinom;Forum;2024-08-28

5. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models;Genome Medicine;2024-08-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3